Brought to you by 
Sinopharm, Merck sign letter of intent for vaccine sales
20 Aug 2010
Executive Summary
China's largest pharmaceuticals company Sinopharm Group Co. (also known under the name China National Pharmaceutical Group Corp., a collection of ten medical businesses) and Merck & Co. Inc. have signed a letter of intent regarding the potential commercialization of Merck's drugs in China.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Preliminary
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sinopharm, Merck sign letter of intent for vaccine sales
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice